Company

RVL Pharmaceuticals

As of the edition of 20 October 2026, RVL Pharmaceuticals runs 2 drugs, 1 of them marketed.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed1
Stopped1
Total2

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Oxymetazolinenone listed13

A route B row is one company at one target.

Where its trials are

  • Immune system: 4 trials led
  • Nervous system: 4 trials led
  • Bones, joints and muscles: 3 trials led